https://orcid.org/0000-0003-1591-2451
Figures
Abstract
The morbidity and mortality of sickle cell disease (SCD) remain high. Novel nonmyeloablative haploidentical hematopoietic cell transplant (HCT) regimens are being proposed.
Methods
This report compared the effect of adding an IV pentostatin and oral cyclophosphamide (PC) preconditioning to the nonmyeloablative NIH HCT platform of alemtuzumab and total body irradiation (TBI) in adults with severe SCD. Transplant outcomes were compared to a historical HCT cohort that did not receive the PC preconditioning.
Results
Thirty-nine adult SCD patients were included. The median age was 33 years, 61% were male, and 92% were HbSS genotype. The median follow-up was 6.5 years. Many patients had severe end-organ damage, including dialysis-dependent end-stage kidney disease (8%) and cirrhosis (10%). One-year overall survival was 95%. The PC regimen was associated with a reduction in acute rejection one-year post-HCT (5% vs. 44%; p = 0.004) and lower graft failure rates throughout the follow-up period. After a median follow-up of 5.2 years, the disease-free survival was 71% for the PC regimen. The PC preconditioning was associated with higher rates of full donor chimerism at 2-years post-HCT (0% vs. 43%; p = 0.02). Grade II-IV acute graft-versus-host disease (GVHD) rates were low; no patients developed moderate to severe chronic GVHD. There remain no cases of myeloid malignancy after PC. With the increased immunosuppression of PC, 23% of patients developed post-transplant lymphoproliferative disorder, 19% developed immune cytopenias, and 62% had viral reactivation.
Citation: Limerick E, Hsieh M, Queen J, Grecco ML, Varga J, Brooks J, et al. (2026) Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease. PLoS One 21(3): e0332282. https://doi.org/10.1371/journal.pone.0332282
Editor: Le Zhang, Sichuan University, CHINA
Received: September 11, 2025; Accepted: January 27, 2026; Published: March 23, 2026
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Data Availability: The datasets analyzed in this study are available in the FigShare data repository, DOI: https://doi.org/10.25444/nhlbi.29963303.
Funding: This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH). The contributions of the NIH author(s) were made as part of their official duties as NIH federal employees, are in compliance with agency policy requirements, and are considered Works of the United States Government. However, the findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services. This research was also supported by the Cooperative Study of Late Effects for SCD Curative Therapies (COALESCE, 1U01HL156620-01, NHLBI). There was no additional external funding received for this study.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Sickle cell disease (SCD) is associated with considerable morbidity and mortality. We and others have shown that adults with organ dysfunction are more likely to die at least 20 years earlier than the general population [1–10]. And those with more than one organ involved are expected to die even earlier [11]. Despite decreased mortality for children with SCD [12–14], the median age of death remains within the 5th decade of life [3].
Hematopoietic cell transplantation (HCT) offers a curative option for individuals with SCD. Myeloablative HLA-matched sibling donor (MSD) HCT is efficacious [15,16] but this approach is limited to younger patients with minimal organ damage. Nonmyeloablative MSD HCT allows the enrollment of patients with compromised organ function. While the NIH approach has minimal GVHD and transplant-related mortality, the disease-free survival (DFS) has been around 85–88% [17,18]. Further, < 15% of patients with SCD have HLA-MSD [19].
Autologous gene therapy and gene editing strategies are being developed; the Food and Drug Administration recently approved two approaches [20,21]. While both strategies showed remarkable efficacy, currently, there is a requirement for myeloablative chemotherapy, substantially limiting access for many adults with SCD given the increased prevalence of hepatopathy, nephropathy, and cardiopulmonary disease with age.
At least 90% of patients with SCD have a parent, child, half-matched sibling, or other relative who could serve as a haploidentical donor [22]. Thus, nonmyeloablative haploidentical HCT could be extended to most adults with SCD, including those with compromised organ function. Our first nonmyeloablative haploidentical HCT study was written as a dose escalation of post-transplant cyclophosphamide (PT-Cy) [23]. All patients received alemtuzumab, 400cGy total body irradiation (TBI), and sirolimus. Adding PT-Cy improved the engraftment rate and DFS with no significant GVHD. However, the DFS was, at best, 50%. In addition, the incidence of myeloid malignancies was unacceptably high, with 3 of 21 patients experiencing myeloid malignancies. The study closed to accrual in 2016.
We and others have worked to optimize nonmyeloablative haploidentical HCT to widen the donor pool with acceptable rates of chronic GVHD and mortality [16,24–30]. Traditionally, our goal has been mixed donor/recipient chimerism to minimize the risk of GVHD, as we found that 20–25% donor myeloid chimerism (DMC) is sufficient to reverse the sickle phenotype [31,32]. Others with a therapeutic goal of full donor chimerism have had excellent DFS and low GVHD rates [16,27] but often excluded patients with severe organ damage and had limited long-term follow-up.
Because of the high rate of acute graft rejection with our original haploidentical HCT study [23], we hypothesized that additional immunosuppression targeting recipient lymphocytes was necessary. Others have shown that pentostatin combined with cyclophosphamide (PC) results in significantly higher recipient T- and B-cell depletion than fludarabine and cyclophosphamide (FC) in a murine model [33]. Importantly, mice receiving PC engrafted at a higher rate and more commonly displayed stable mixed chimerism than FC. In a pilot HCT study in 10 patients with metastatic renal cell carcinoma using PC conditioning [34], recipient t-cells were effectively depleted without severe neutropenia; all 10 patients engrafted with stable mixed chimerism, even after discontinuing sirolimus. We, therefore, sought to develop a nonmyeloablative haploidentical HCT regimen that included PC preconditioning (haplo-PC), which would maximize long-term efficacy while minimizing toxicity, and could be offered to patients with compromised organ function. We also strove to evaluate whether the addition of PC conditioning impacted transplant outcomes, including the acute graft rejection rate, overall survival, DFS, the incidence of GVHD and viral complications, and the timing of lymphocyte reconstitution, compared to the original haploidentical protocol. We hypothesized PC would improve acute graft rejection rates while minimizing toxicity and maintaining low rates of GVHD.
Materials and methods
This report compares the results of NIH’s two nonmyeloablative haploidentical HCT regimens. The National Heart, Lung, and Blood Institute Institutional Review Board approved both studies. Patients with severe SCD were referred for participation and comprehensively evaluated in an outpatient setting prior to enrollment. All patients gave written informed consent. An independent data and safety monitoring board monitored the studies. Our first haploidentical protocol (haplo-1; NCT00977691) began enrolling in 2009 and employed alemtuzumab and TBI-based conditioning with dose-escalating PT-Cy and sirolimus for GVHD prophylaxis in adults with severe SCD; the results of this study have been previously reported [23]. While all patients are included in descriptive reporting of significant adverse events, these analyses excluded patients who did not receive PT-Cy (n = 3); patients who received repeat transplants were censored at the time of repeat HCT.
The second NIH haploidentical study (haplo-PC), which recruited from February 2017 through June 2023, was a prospective phase 1/2 nonmyeloablative haploidentical peripheral blood stem cell (PBSC) transplant protocol for patients with severe SCD (NCT03077542). The initial inclusion criteria included any type of SCD with history of stroke, tricuspid regurgitant velocity (TRV) ≥ 2.5 m/s with or without right heart catheterization -documented pulmonary hypertension [7], sickle hepatopathy [35], defined as ferritin >1000 mcg/L and platelet count <250,000/µL or direct bilirubin >0.4 mg/dL and platelet count <250,000/µL; patients with frank cirrhosis, defined based on liver biopsy, were also included, recurrent vaso-occlusive crises, or recurrent acute chest syndrome. Due to a higher-than-expected rate of complications, the details of which will be discussed in this report, the inclusion criteria were updated in 2022 to only include patients with higher risk disease: stroke, TRV ≥ 2.7 m/s with or without pulmonary hypertension, sickle hepatopathy (as defined above), acute chest syndrome requiring intensive care admission, or silent infarcts; patients with recurrent vaso-occlusive crises in the absence of other organ manifestations were no longer included.
At the time of enrollment, patients had to be at least 18 years of age, have a haploidentical related donor available, ejection fraction ≥35%, glomerular filtration rate (GFR) >60 mL/min/1.73 m2 (this was due to the addition of pentostatin and differs from the haplo-1 protocol in which there was no exclusion based on renal function; indeed patients with dialysis-dependent end-stage kidney disease (ESKD) were included on haplo-1) and adjusted diffusing capacity of the lungs for carbon monoxide ≥35%. Patients with donor-specific anti-HLA antibodies with a mean fluorescence intensity ≥2000 [36] and recipients seronegative for Epstein-Barr Virus (EBV) who had EBV seropositive donors [37] were excluded. Fig 1 summarizes study enrollment numbers.
All patients received PC preconditioning with 4 doses of intravenous pentostatin (4 mg/m2) given over 60 minutes on days −21, −17, −13, and −9 (Fig 2); PC was administered in the outpatient setting. Estimated GFR (eGFR) was calculated before each dose of pentostatin, and the dose was adjusted as necessary. Although an eGFR at time of protocol enrollment >60 mL/min/1.73 m2 was required, pentostatin is associated with a risk of severe renal toxicity. S1 Table summarizes the pentostatin dose adjustment schema as necessary after pentostatin initiation. Oral cyclophosphamide (Cy) was self-administered on day −21 until day −8 at 200 mg/day. To maximize recipient lymphodepletion, the goal absolute lymphocyte count (ALC) before alemtuzumab was < 100/µL. The goal absolute neutrophil count (ANC) before alemtuzumab was ≥ 1,000/µL to prevent excessive and prolonged myelosuppression. Cy dosing was adjusted per protocol to achieve the desired ALC and ANC goals (S2 Table).
Pento: pentostatin; TBI: total body irradiation; G-CSF: granulocyte colony-stimulating factor; PBSC: peripheral blood stem cell; PT-Cy: post-transplant cyclophosphamide.
Patients were admitted at least 1 week prior to HCT and received a total 1 mg/kg of alemtuzumab infused over 2 hours on days −7 to −3 before PBSC infusion. The first 20 patients received 400cGy TBI in 2 divided doses on days –2 and –1 before PBSC infusion; patients 20–22 received 400cGy TBI as a single fraction. Post-transplant cyclophosphamide was infused as a single dose of 50 mg/kg on day + 3 based on our prior experience of higher rates of viral reactivation with two doses [23]. A sirolimus trough level of 10–12 ng/mL was targeted until 3–4 months post-HCT, and then the level was decreased to 5–10 ng/mL in engrafted patients. Sirolimus was generally continued as tolerated in engrafted patients until at least 1-year post-HCT or until the patients achieved full donor chimerism (≥95% DMC and ≥95% donor lymphoid chimerism (DLC)).
Recipients positive for cytomegalovirus (CMV) received letermovir prophylaxis from day −21–100 days post-HCT. The goal hemoglobin level after the start of alemtuzumab was 9 g/dL and a platelet count of 50,000/µL. Additional supportive care was provided as previously described [23] and per the protocol. Donors received 5–6 days of granulocyte colony-stimulating factor at 10 to 16 μg/kg/d for mobilization, followed by peripheral blood leukapheresis with a goal of at least 10 × 106 CD34 cells per kilogram of the recipient’s body weight. The PBSC products were subsequently cryopreserved [38].
The primary endpoint was to define the percentage of patients at 100 days (+/- 1 week) post-transplant who have not rejected their grafts and who are without severe GVHD. In this analysis, we examined rates of graft rejection at one year post-HCT, in order to capture all episodes of early rejection, as well as graft failure at the last follow-up. Graft rejection refers to an acute loss of the graft, with <5% DMC and DLC. Graft failure includes those with graft rejection, but also includes patients with return of acute complications of SCD, regardless of whether donor cells remained detectable. Secondary endpoints included disease-free and overall survival, chimerism levels, rates of GVHD, as well as viral reactivation and disease. Planned follow-up occurred 1 to 2 times per week until 100 days post-HCT, every 6 months until 2 years post-HCT, and annually thereafter. (Clinical trial protocol available in supplemental materials)
Laboratory studies, including hematologic studies, chemistries, and lymphocyte subsets, were run at the NIH Department of Laboratory Medicine. Lineage-specific chimerism studies (CD14/CD15 and CD3) were conducted as previously described [39,40]. Donor red cell chimerism was assessed by hemoglobin electrophoresis and extended red blood cell (RBC) phenotyping; the NIH Department of Transfusion Medicine performed RBC phenotyping and HLA antibody analyses.
The haplo-PC trial was designed to enroll 39 individuals; with this sample size, if the true success rate is 70% or more, there is 80% power for concluding further development is possibly warranted. Stopping rules for efficacy as well as toxicity (severe acute or chronic GVHD, viral disease not controllable by anti-viral therapy) were in place. The cumulative incidence of graft rejection at one-year post-HCT and graft failure at last follow-up were computed for each protocol, treating death without a prior graft failure as a competing risk. Tests of the equivalence of cumulative incidence of graft failure between the two protocols were based on Gray’s test [41] and implemented using the cmprsk package in the R statistical language. Kaplan-Meier analyses of DFS do not require accounting for competing risk, as both death and graft failure count as events—this analysis was implemented in the survival package of the R language. Comparisons of categorical outcomes between protocols were made with Fisher’s exact test, and continuous variables with the Wilcoxon rank sum test.
Results
The cohort included 39 patients (18 on haplo-1 and 21 on haplo-PC) who were predominantly male (61%) and HbSS genotype (92%) (Table 1). The mean recipient age on the haplo-1 protocol was 36 years, while the mean recipient age on the haplo-PC protocol was 32 years. The mean donor age was 45 and 33 years on haplo-1 and haplo-PC, respectively. There were 18 (46%) patients on haplo-1 and 21 (54%) on haplo-PC. Most patients (90%) had a history of hydroxyurea use, and a substantial portion (38%) required regular transfusion therapy prior to HCT. Clinical complications were numerous, including elevated TRV (62%), RBC alloimmunization (46%), acute chest syndrome requiring ICU admission (41%), sickle hepatopathy (38%), and stroke (36%) (Table 1). This cohort included patients often excluded from other curative therapies, including those with cirrhosis (n = 3) and ESKD requiring dialysis (n = 4). Indeed, 37% of US patients in this cohort were ineligible for what is becoming the most common haploidentical HCT approach for adults with SCD [27,42,43]. There was a significantly higher proportion of patients with sickle nephropathy on haplo-1 than haplo-PC. There were more patients with a history of hydroxyurea use on haplo-PC than haplo-1. Finally, the CD3 cell dose was higher on haplo-1 than haplo-PC; otherwise, baseline donor and recipient characteristics were similar between the two protocols.
One-year overall survival was 95%; in the first year, there was 1 death on each protocol. Table 2 summarizes the post-HCT outcomes. At one-year post-HCT, there was more acute rejection on the haplo-1 study compared to the haplo-PC group (44% vs. 5%, p = 0.004) (Fig 3). The median follow-up was longer for the haplo-1 than the haplo-PC cohort (10.1 vs. 5.2 years; p < 0.0001). The improved rates of sustained engraftment in the haplo-PC cohort were maintained throughout the follow-up period.
We compared graft status at last follow-up: for patients who died during the follow-up period, we report their graft status at the time of death. Fig 4 shows 86% of patients had sustained engraftment at last follow-up in the haplo-PC cohort compared with 33% in haplo-1 (p = 0.006). These differences were maintained even when the subgroups of haplo-1, which received 50 mg/kg and 100 mg/kg of post-transplant cyclophosphamide respectively, were individually compared to haplo-PC in terms of time to graft failure (S1 Fig). We examined regression models for time to graft failure that incorporated the three baseline variables that were different between the protocols (presence of nephropathy, use of hydroxyurea, and CD3 dose) and found that protocol retained significant explanatory power when adjusting for each variable separately; the added variables were not significant in terms of explaining the time to graft failure (p-values of 0.26, 0.75, 0.62, respectively).
Late graft failure has been noted; two haplo-PC patients with slowly falling chimerism are being closely followed. Their most recent DMC levels were 15 and 16%, while hemoglobin electrophoresis showed 49.5 and 39.7% HbS at 5 and 7 years post-HCT, respectively; both donors have sickle cell trait. Overall survival at last follow-up was 67% on haplo-1 and 86% on haplo-PC. Fig 5 demonstrates that the DFS at the last follow-up was 33% (haplo-1) and 71% (haplo-PC); these differences show a trend towards improvement in DFS with the addition of PC (p = 0.06). Five patients on the haplo-1 trial had repeat transplants in the setting of return of SCD: one died of intracranial hemorrhage 60 days after her repeat HCT in the setting of thrombocytopenia while receiving rituximab for EBV-associated post-transplant lymphoproliferative disorder (PTLD); another died from COVID-19 less than 1 year from the second transplant; a third patient who experienced graft failure received the transplant for AML and died of relapse. The remaining two repeat HCT patients are alive and free of SCD. Only one patient on the haplo-PC trial received a repeat transplant; that patient is alive and free of SCD.
No patients on the haplo-1 protocol and two (10%) patients on the haplo-PC protocol developed grade II-IV acute GVHD (one grade II, one grade IV). No patients on either protocol developed moderate to severe chronic GVHD.
We examined rates of full donor chimerism compared to mixed chimerism in patients free of SCD at 2-years post-HCT. On haplo-1, 0 of 10 (0%) patients had full donor chimerism while 6 of 14 (43%) haplo-PC patients had full donor chimerism (p = 0.02). Fig 6A and 6B compare the mean donor chimerism levels between the protocols.
Of the patients who were alive and free of SCD at last follow-up, 4 (67%) haplo-1 patients and 11 (73%) in the haplo-PC cohort were off immunosuppression. Table 2 summarizes complications and outcomes after HCT. While 16 (89%) of haplo-1 patients experienced an episode of febrile neutropenia, ten (48%) patients on haplo-PC had a neutropenic fever early post-HCT (p = 0.008). One patient on the haplo-1 protocol and two patients on haplo-PC experienced sepsis early after HCT (6% and 10% for haplo-1 and haplo-PC, respectively). There was a trend towards more viral reactivation (EBV, CMV) on the haplo-PC protocol than haplo-1: 62% versus 28% (p = 0.05). Viral disease (adenovirus and CMV) rates were 17% and 0%, on haplo-1 and haplo-PC, respectively (p = 0.21).
Three of 21 (14%) patients who received HCT on haplo-1 experienced myeloid malignancies, and no patients on haplo-PC (0%). However, as one patient from haplo-1 was excluded from the analysis since she did not receive PT-Cy, for the purpose of this analysis, 2 patients on haplo-1 developed a myeloid malignancy (11%) versus 0 patients on haplo-PC (p > 0.05). Five of 22 patients (23%) who underwent HCT on haplo-PC developed PTLD, and no patients on haplo-1 (0%). Two patients developed severe, refractory PTLD treated with systemic chemotherapy and virus-specific t-cells. These therapies led to remission of PTLD in both patients, though one died of complications of therapy (methotrexate-induced leukoencephalopathy). Three patients received rituximab alone, one of these patients, as previously noted, died secondary to intracranial hemorrhage. For the analysis, this one patient, who developed PTLD after a repeat HCT on haplo-PC (after her initial HCT on haplo-1), was excluded, and 4 patients on haplo-PC developed PTLD (19%) versus 0 patients on haplo-1 (p > 0.05).
There were more immune complications, including Evans syndrome (n = 2) and autoimmune hemolytic anemia (n = 2; S3 Table), in the haplo-PC protocol than haplo-1: 19% versus 0%, respectively (p = 0.11). While these differences are not statistically significant, in part due to the small sample size, they are indeed clinically important. The presence of two lethal cases of Evans syndrome contributed to the modification of the protocol’s inclusion criteria and TBI administration in 2022. Although data suggest that DLC changes at 6 months may predict the subsequent development of immune cytopenias [44], we saw no such changes in our population (S2 Fig).
Two patients on haplo-PC had biopsy-proven cirrhosis. Both tolerated the conditioning without significant event; neither experienced graft failure and both had full donor chimerism at last follow-up. One of these patients developed EBV-driven PTLD and died due to complications of PTLD therapy. Only one patient had detectable donor-specific HLA antibodies prior to HCT, though at the time of transplant they were no longer detectable. The patient remains engrafted and free of SCD at last follow-up. Eighteen (46%) patients had a reported history of alloimmunization prior to HCT; 17 (44%) had a specific RBC antibody identified at some point prior to HCT. There were three (8%) patients who received HCT from donors against whose RBC antigens they had a documented RBC antibody; none of these patients experienced graft failure.
The additional immunosuppression of the PC pre-conditioning in the haplo-PC protocol did not delay lymphocyte reconstitution. Fig 7 shows that the expected drop in lymphocyte counts in the early post-HCT period is similar between groups. Further, both protocols demonstrate a return to pre-HCT CD3, CD4, CD8, and CD19 counts by two years (Fig 7A-7D).
Discussion
Outcomes of haploidentical HCT for SCD have improved markedly since early studies, which were marred by high rates of graft rejection [22,23]. Indeed, 88–95% event-free survival at 2 years for adults has been reported after bone marrow transplantation with reduced-intensity fludarabine, cyclophosphamide, antithymocyte globulin, thiotepa, and 200cGy TBI conditioning [27,30,45]. These excellent results rival the success of nonmyeloablative MSD HCT [17]. Murine studies demonstrate that the PC is nonmyeloablative, with significantly less marrow ablation than lethal doses of TBI despite profound immune depletion [33]. The regimen is nonmyeloablative, but consideration of toxicities remains important. The use of post-transplant cyclophosphamide has markedly improved HCT outcomes in the haploidentical setting; other nonmyeloablative and RIC regimens report similarly strong overall and disease free survival rates to what we report with the PC regimen, as well as low rates of acute and chronic GVHD, particularly in the first 1–2years of transplant [25,26,28–30]. These data highlight the import of long-term patient follow-up; the 5 and 10 years of median follow-up for the two NIH studies reported here is exceptional.
The impact of SCD comorbidities is dire: multi-system end-organ impairment was associated with a 4.2-fold increase in mortality risk [11]. Thus, access to potentially curative therapies that include patients with severe disease and end-organ damage is critical. The minimally toxic NIH regimens have been employed in patients often excluded from other protocols, including those with ESKD requiring dialysis, cirrhosis, and severe pulmonary hypertension [23,46]. Indeed, 37% of US patients we transplanted would have been excluded from the Blood and Marrow Transplant Clinical Trials Network 1507 study, which employs a regimen identical to the Vanderbilt study. Thus, there remains an urgent need for efficacious HCT regimens for adults with SCD and severe end-organ damage.
As expected based on the murine and non-SCD clinical data described above [32,42], as well as recently published data in the matched sibling HCT for SCD setting [47], we demonstrate that PC substantially reduced the high rates of acute graft rejection and well as graft failure at last follow-up, likely due to the intensified lymphodepletion and host t-cell suppression. Late graft failures presented a challenge on both protocols, with a trend toward improved DFS with the addition of PC: 4 patients on the haplo-1 protocol had slowly falling chimerism and return of SCD, even as far as 10 years post-HCT; two patients on the haplo-PC protocol had falling chimerism with SCD recurrence. Another 2 patients have falling chimerism and may experience graft failure despite prolonged courses of immunosuppression. In the setting of mixed and waning chimerism, some patients have continued immunosuppression for years despite the absence of cGVHD. Future studies to determine when tolerance has been achieved and immunosuppression can be safely discontinued are important.
Repeat HCT with myeloablative conditioning and stem cells from the original donor for those with falling but persistent DMC and return of SCD is being investigated with an ongoing study (NCT04008368). This strategy employs busulfan-based conditioning with the addition of serotherapy with alemtuzumab, theorizing that immune tolerance was achieved in the first transplant, as evidenced by the persistent DMC, but adequate space must be created in the marrow for enduring engraftment.
The improved graft rejection rates associated with the PC regimen came at the cost of increased toxicity. Specifically, higher rates of viral reactivation and EBV-driven PTLD. A 2022 survey of international transplant centers regarding EBV infection demonstrated an overall frequency of EBV-PTLD of 1.28% in adults and 2.38% for haploidentical HCT with PT-Cy [48]. Despite the exclusion of EBV seropositive donors with seronegative recipients, the rate of EBV-PTLD was 23% on the haplo-PC protocol. Ultimately, EBV-PTLD contributed to death in 40% (2/5) of PTLD patients on the haplo-PC protocol. A similar pentostatin-cyclophosphamide pre-conditioning regimen with half the pentostatin dose was recently reported in the setting of matched sibling HCT for SCD [47]. In that setting, higher viral reactivation rates were reported with the addition of preconditioning without PTLD. In the era of regular PCR monitoring of EBV and pre-emptive treatment with rituximab, 30% mortality has been reported with PTLD [49]. Whereas we initially deferred treatment for PTLD until EBV DNAemia was persistent and rising and/or symptomatic, we have pivoted to earlier treatment with rituximab at the first detection of EBV viremia, similar to the highest risk cord blood transplant recipients [50]. Further, protocols employing PC may consider pre-transplant rituximab; evidence suggests a single dose given prior to HCT can significantly mitigate the risk of both EBV reactivation and PTLD with minimal toxicity [51]. This exceptionally high risk of PTLD and other complications as described above led to the early closure to enrollment on the haplo-PC protocol in 2023. Thus, the haplo-PC protocol did not enroll the 39 patients originally intended; therefore power to detect differences is limited.
Further, immune-mediated cytopenias were noted in four patients on the haplo-PC protocol, in two of whom it was refractory to treatment and resulted in death; no such complications were seen on the haplo-1 protocol. The pathogenesis of post-HCT cytopenias has not been completely elucidated, but delayed immune reconstitution post-HCT has been proposed [52]. Interestingly, our data do not demonstrate a difference between the protocols in total lymphocyte, CD4, CD8, or B-cell reconstitution post-HCT. Importantly, the addition of PC does not seem to impact the timing of hematologic reconstitution or increase the likelihood of febrile neutropenia, sepsis, or infection. Although viral reactivation trended up with the addition of PC, viral disease rates were unchanged, highlighting a potential implication of increased lymphodepletion. Patients with more refractory cytopenia affecting multiple cell lines both had mixed lymphocyte chimerism at the time of diagnosis. Others have reported significantly lower CD3 + T lymphocyte donor chimerism at day + 180 post-HCT in those who develop immune cytopenias [44]; we did not note any such decline. We hypothesize that high rates of PTLD and viral reactivation can be explained by excessive immunoablation, likely from the combination of PC, proximal alemtuzumab, and PT-Cy. This trifecta effectively handicaps host and recipient t-cells, rendering them increasingly susceptible to pre-existing viruses. This is an ongoing area of study in our lab.
We amended our protocol to increase myeloablation, changing from 400cGy given in 2 fractions to 400cGy given as a single fraction, with a goal of maintaining higher donor chimerism to help mitigate the risk of these immune-mediated complications and late graft failure. We hypothesized that the increased marrow suppression of the single fraction of TBI would give the donor cells an advantage and thereby improve and sustain donor chimerism, thereby mitigating immune complications seen more in mixed chimera patients [53]. No immune-mediated cytopenias were seen in patients who received the single fraction of TBI, all of whom had full donor myeloid and lymphocyte chimerism at last follow-up; but the sample size is inadequate. Further adjustments may be considered in the future, including PC dose reduction. Others have employed two to three doses of pentostatin, with or without cyclophosphamide, with excellent engraftment rates and no reported PTLD or immune cytopenias [54–56].
Some limitations of the study should be noted. The majority, > 90%, of patients were HbSS genotype; we are therefore unable to assess the efficacy and toxicity of the pentostatin-cyclophosphamide pre-conditioning in non-HbSS genotypes. While no patients on the haplo-PC protocol have developed a myeloid malignancy, enthusiasm should be dampened by the shorter period of median follow-up compared to the haplo-1 study. However, the lower graft rejection rate and higher incidence of full donor chimerism in haplo-PC compared to haplo-1 may have contributed to a lower risk for myeloid malignancies. Further, as noted above, the haplo-PC closed to accrual prior to meeting stated enrollment goals resulting in a small sample size. Power to detect difference is limited.
Conclusion
Nonmyeloablative haploidentical HCT for SCD with PC preconditioning decreased acute graft rejection and long-term engraftment rates with minimal GVHD; there was also a trend towards improved DFS when compared to the haplo-1 regimen. While the original haploidentical trial had unacceptably high rates of graft rejection and myeloid malignancies that were mitigated in the haplo-PC protocol, complications associated with the haplo-PC protocol include viral reactivation, PTLD, and immunohematologic complications. The NIH enrolls patients with more severe disease compared to more standard haploidentical protocols, so results should be interpreted considering this. A novel nonmyeloablative haploidentical regimen for patients with SCD and compromised organ function is desperately needed.
Supporting information
S1 Table. eGFR-based Pentostatin Dosing.
Estimated GFR (eGFR) was calculated before each dose of pentostatin, with the dose adjusted as noted above. The GFR was calculated based on cystatin-C using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) GFR calculation; in the absence of cystatin-C data, the Cockcroft-Gault formula was used.
https://doi.org/10.1371/journal.pone.0332282.s001
(PDF)
S2 Table. Protocol for cyclophosphamide dose adjustment.
1 Pentostatin will not be dose-adjusted based on ALC/ANC values. 2 For ANC values <1000, decrease in cyclophosphamide dosing only – patients will not receive G-CSF. 3 Cyclophosphamide dose indicated will be continued daily until the next ALC/ANC measurements.
https://doi.org/10.1371/journal.pone.0332282.s002
(PDF)
S3 Table. Summary of immune-mediated hematologic complications after HCT on Haplo-1 and Haplo-PC protocols.
HCT: hematopoietic cell transplant, IVIG: intravenous immunoglobulin.
https://doi.org/10.1371/journal.pone.0332282.s003
(PDF)
S1 Fig. Graft failure at last follow-up
a)Cumulative incidence of graft failure at last follow-up in patients receiving 50 mg/kg PT-Cy on haplo-1 and all haplo-PC patients (who also received 50 mg/kg PT-Cy) b) Cumulative incidence of graft failure at last follow-up in patients receiving 100 mg/kg PT-Cy on haplo-1 and all haplo-PC patients.
https://doi.org/10.1371/journal.pone.0332282.s004
(PDF)
S2 Fig. 6-month donor lymphocyte chimerism in all patients with and without immunohematologic complications.
https://doi.org/10.1371/journal.pone.0332282.s005
(PDF)
S3 Fig. 17H0069 Protocol AmFF 15JUN24.SUPPpdf.
https://doi.org/10.1371/journal.pone.0332282.s006
(PDF)
Acknowledgments
We would like to express our appreciation to Drs. Tom Hughes, Deb Citrin, David Stroncek, Bill Flegel, Luigi Notarangelo, as well as NP Donna Chauvet and PA Shawn Chong, for their support in implementing the protocol and providing clinical care to our patients.
References
- 1. Chaturvedi S, Labib Ghafuri D, Kassim A, Rodeghier M, DeBaun MR. Elevated tricuspid regurgitant jet velocity, reduced forced expiratory volume in 1 second, and mortality in adults with sickle cell disease. Am J Hematol. 2017;92(2):125–30. pmid:27806442
- 2. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81(11):858–63. pmid:16924640
- 3. DeBaun MR, Ghafuri DL, Rodeghier M, Maitra P, Chaturvedi S, Kassim A, et al. Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis. Blood. 2019;133(6):615–7. pmid:30530750
- 4. Fitzhugh CD, Hsieh MM, Allen D, Coles WA, Seamon C, Ring M, et al. Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia. PLoS One. 2015;10(11):e0141706. pmid:26576059
- 5. Fitzhugh CD, Lauder N, Jonassaint JC, Telen MJ, Zhao X, Wright EC, et al. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol. 2010;85(1):36–40. pmid:20029950
- 6. Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep. 2013;128(2):110–6. pmid:23450875
- 7. Maitra P, Caughey M, Robinson L, Desai PC, Jones S, Nouraie M, et al. Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Haematologica. 2017;102(4):626–36. pmid:28104703
- 8. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–44. pmid:7993409
- 9. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005;84(6):363–76. pmid:16267411
- 10. Powars DR, Elliott-Mills DD, Chan L, Niland J, Hiti AL, Opas LM, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med. 1991;115(8):614–20. pmid:1892333
- 11. Chaturvedi S, Ghafuri DL, Jordan N, Kassim A, Rodeghier M, DeBaun MR. Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study. Am J Hematol. 2018;93(9):1153–60. pmid:29981283
- 12. Couque N, Girard D, Ducrocq R, Boizeau P, Haouari Z, Missud F, et al. Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines. Br J Haematol. 2016;173(6):927–37. pmid:27062606
- 13. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17):3447–52. pmid:20194891
- 14. Telfer P, Coen P, Chakravorty S, Wilkey O, Evans J, Newell H, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica. 2007;92(7):905–12. pmid:17606440
- 15. Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11):1548–56. pmid:27965196
- 16. Lawal RA, Walters MC, Fitzhugh CD. Allogeneic Transplant and Gene Therapy: Evolving Toward a Cure. Hematol Oncol Clin North Am. 2022;36(6):1313–35. pmid:36400545
- 17. Alzahrani M, Damlaj M, Jeffries N, Alahmari B, Singh A, Rondelli D, et al. Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. Br J Haematol. 2021;192(4):761–8. pmid:33534948
- 18. Damlaj M, Alahmari B, Alaskar A, Alhejazi A, Alsadi H, Ahmed M, et al. Favorable outcome of non-myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients. Am J Hematol. 2024;99(6):1023–30. pmid:38488686
- 19. Walters MC, Patience M, Leisenring W, Eckman JR, Buchanan GR, Rogers ZR, et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 1996;2(2):100–4. pmid:9118298
- 20. Frangoul H, et al. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024;390(18):1649–62.
- 21. Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, et al. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. N Engl J Med. 2022;386(7):617–28. pmid:34898139
- 22. Bolaños-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285–91. pmid:22955919
- 23. Fitzhugh CD, Hsieh MM, Taylor T, Coles W, Roskom K, Wilson D, et al. Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Adv. 2017;1(11):652–61. pmid:29296707
- 24. Bolaños-Meade J, Cooke KR, Gamper CJ, Ali SA, Ambinder RF, Borrello IM, et al. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematol. 2019;6(4):e183–93. pmid:30878319
- 25. de la Fuente J, Dhedin N, Koyama T, Bernaudin F, Kuentz M, Karnik L, et al. Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative. Biol Blood Marrow Transplant. 2019;25(6):1197–209. pmid:30500440
- 26. Frangoul H, et al. Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy tbi and post transplant cyclophosphamide. Bone Marrow Transplant, 2018;53(5):647–50.
- 27. Kassim AA, de la Fuente J, Nur E, Wilkerson KL, Alahmari AD, Seber A, et al. An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease. Blood. 2024;143(25):2654–65. pmid:38493482
- 28. Pawlowska AB, Cheng JC, Karras NA, Sun W, Wang LD, Bell AD, et al. HLA haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease. Biol Blood Marrow Transplant. 2018;24(1):185–9. pmid:28939451
- 29. Saraf SL, Oh AL, Patel PR, Sweiss K, Koshy M, Campbell-Lee S, et al. haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease. Biol Blood Marrow Transplant. 2018;24(8):1759–65. pmid:29656137
- 30. Kassim AA, et al. Haploidentical bone marrow transplantation for sickle cell disease. NEJM Evid. 2025;4(3):EVIDoa2400192.
- 31. Fitzhugh CD, Cordes S, Taylor T, Coles W, Roskom K, Link M, et al. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood. 2017;130(17):1946–8. pmid:28887325
- 32. Abraham A, Hsieh M, Eapen M, Fitzhugh C, Carreras J, Keesler D, et al. Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2017;23(12):2178–83. pmid:28882446
- 33. Mariotti J, Taylor J, Massey PR, Ryan K, Foley J, Buxhoeveden N, et al. The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection. Biol Blood Marrow Transplant. 2011;17(5):620–31. pmid:21130889
- 34. Mossoba ME, Halverson DC, Kurlander R, Schuver BB, Carpenter A, Hansen B, et al. High-dose sirolimus and immune-selective pentostatin plus cyclophosphamide conditioning yields stable mixed chimerism and insufficient graft-versus-tumor responses. Clin Cancer Res. 2015;21(19):4312–20. pmid:26071480
- 35. Feld JJ, Kato GJ, Koh C, Shields T, Hildesheim M, Kleiner DE, et al. Liver injury is associated with mortality in sickle cell disease. Aliment Pharmacol Ther. 2015;42(7):912–21. pmid:26235444
- 36. Ciurea SO, et al. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(8):1392–8.
- 37. Law N, Logan C, Taplitz R. EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) recipients and its impact on HSCT outcomes. Viruses. 2024;16(8):1294. pmid:39205268
- 38. Kang EM, et al. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood. 2002;99(3):850–5.
- 39. Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361(24):2309–17. pmid:20007560
- 40. Nollet F, Billiet J, Selleslag D, Criel A. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant. 2001;28(5):511–8. pmid:11593326
- 41. Gray RJ. A Class of $K$-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16(3).
- 42. Alasbali R, Alzahrani M, Alhayli S, Rasheed W, Akhom P, Wilkerson K, et al. Excellent Outcomes of HLA matched related donor transplant for adults with severe sickle cell disease using a non-myeloablative conditioning with thiotepa and post-transplant cyclophosphamide: multi-center international experience. Blood. 2023;142(Supplement 1):1042–1042.
- 43. Kassim AA, et al. Reduced intensity haploidentical bone marrow transplantation in adults with severe sickle cell disease: BMT CTN 1507. Blood. 2023;142.
- 44. Galvin RT, Cao Q, Miller WP, Knight-Perry J, Smith AR, Ebens CL. Characterizing immune-mediated cytopenias after allogeneic hematopoietic cell transplantation for pediatric nonmalignant disorders. Transplant Cell Ther. 2021;27(4):316.e1-316.e8. pmid:33836874
- 45. Kassim AA, Wilkerson K, de la Fuente J, Seber A, Gouveia RV, Bonfim C, et al. Outcomes of Non-Myeloablative HLA-haploidentical bone marrow transplant with thiotepa and post-transplant cyclophosphamide in children and adults with sickle cell disease, a phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2). Blood. 2022;140(Supplement 1):2383–5.
- 46. Pittman C, Hsieh MM, Coles W, Tisdale JF, Weir NA, Fitzhugh CD. Reversal of pre-capillary pulmonary hypertension in a patient with sickle cell anemia who underwent haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2017;52(4):641–2. pmid:28067884
- 47. Inam Z, Jeffries N, Link M, Coles W, Pollack P, Luckett C, et al. Two Nonmyeloablative HLA-matched related donor allogeneic hematopoietic cell transplantation regimens in patients with severe sickle cell disease. Transplant Cell Ther. 2025;31(5):305–18. pmid:40010689
- 48. Styczynski J, Tridello G, Wendel L, Knelange N, Cesaro S, Gil L, et al. Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT: survey of Infectious Diseases Working Party EBMT. Bone Marrow Transplant. 2024;59(1):59–65. pmid:37872300
- 49. Marjanska A, Styczynski J. Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2023;23(6):539–52. pmid:36971380
- 50. Blaes AH, Cao Q, Wagner JE, Young J-AH, Weisdorf DJ, Brunstein CG. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2010;16(2):287–91. pmid:19835968
- 51. Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, et al. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leuk Lymphoma. 2019;60(7):1693–6. pmid:30741059
- 52. Gabelli M, Ademokun C, Cooper N, Amrolia PI. Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant setting. Br J Haematol. 2022;196(1):45–62. pmid:34195990
- 53. Neely JA, et al. Autoimmune cytopenias in pediatric hematopoietic cell transplant patients. Front Pediatr. 2019;7:171.
- 54. Dimitrova D, et al. Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases. Biol Blood Marrow Transplant. 2020;26(1):94–106.
- 55. Miller KB, Roberts TF, Chan G, Schenkein DP, Lawrence D, Sprague K, et al. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant. 2004;33(9):881–9. pmid:14990986
- 56. Pavletic SZ, Bociek RG, Foran JM, Rubocki RJ, Kuszynski CA, Wisecarver JL, et al. Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. Transplantation. 2003;76(5):877–81. pmid:14501873